As you may know, blocking the receptor binding domain (RBD) of novel coronavirus could be very effective to prevent more severe effects of the inflammation. So, can a BsAb co-targeting CD8+ t cells and recombinant RBD protein (S1 or S2) of SARS-CoV-2 be sufficient to generate a good population of memory CD8 T cells against the future exposes to the virus?